AstraZeneca announced positive topline results from a third Phase III study of tozorakimab in adults with chronic obstructive pulmonary disease (COPD) who have a history of exacerbations despite standard therapy. The company previously reported that tozorakimab met primary endpoints in the OBERON and TITANIA Phase III trials by reducing the annual rate of moderate-to-severe COPD exacerbations versus placebo on top of inhaled maintenance treatment.
In the earlier Phase III studies, tozorakimab, administered subcutaneously in addition to standard of care, significantly reduced moderate-to-severe annualized COPD exacerbations compared with placebo across a broad patient population that included current and former smokers and patients with varying lung function and inflammatory profiles. AstraZeneca has reported that tozorakimab was generally well tolerated in these trials, with a safety profile consistent across studies.
Tozorakimab is a monoclonal antibody targeting interleukin-33 (IL‑33), an alarmin cytokine implicated in airway inflammation and mucus dysfunction in COPD. By inhibiting IL‑33 signaling in both its reduced and oxidized forms, the drug is intended to reduce exacerbations and address key pathophysiologic drivers of COPD. AstraZeneca is also conducting additional Phase III studies, including the open-label PROSPERO trial and the MIRANDA trial, to further characterize the long-term safety and efficacy of tozorakimab in patients prone to COPD exacerbations.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!